Azorsa et al. BMC Genomics 2010, 11:25 http://www.biomedcentral.com/1471-2164/11/25 Additional file 1: Total tau and 12E8 tau data for all siRNAs in the Qiagen Kinome siRNA library. All data from the kinome siRNA library screen. p Tau refers to 12E8 tau. Cumulative results columns represent the average of the three independent experiments reported. Click here for file [ http://www.biomedcentral.com/content/supplementary/1471-2164-11- 25-S1.XLS ] Abbreviations All are defined in the text upon first use. Acknowledgements This work was supported by R21AG029576, K01AG024079, P30AG19610 to TD, RO1 AG023193 and P30AG19610 to DAS, and a charitable contribution to TGen from the Louis Charitable Trust. With also thank Dr. Peter Seubert (Elan Pharmaceuticals) for providing the 12E8 antibody. Author details 1Neuorgenomics Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA. 2Pharmaceutical Genomics Division, Translational Genomics Research Institute, Scottsdale, Arizona, 85251, USA. 3Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 4Center for Alzheimer’s Research, Sun Health Research Institute, Sun City, Arizona, USA. 5Banner Alzheimer’s Institute and Department of Psychiatry, University of Arizona, Phoenix, AZ, USA. 6Arizona Alzheimer’s Consortium, Phoenix, AZ, USA. 7Senior Director, Neuroscience Drug Discovery, Merck and Co Ltd., BMB8- 106, 33 Avenue Louis Pasteur, Boston MA 02115, USA. 8Department of Molecular Pharmacology and Physiology, College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd, MDC 8, Tampa, FL 33612, USA. Authors’ contributions All authors have read and approved the final manuscript. DOA, RR (developed the siRNA screrening assay and led and performed target validation efforts); GRB, CB, GDB, DRH, JAH, KMB, LG, AG, JR (assisted with siRNA assay development); CD(helped generate the H4-tau cell line); DF, BM (assisted with kinase validation experiments); EMR, Hutton MH, DAS, SM (provided critical review of manuscript and helped with interpretation of results); TD (Led the development of the siRNA screening assay, the interpretation of results, the selection of kinases for validation, and wrote the manuscript). All authors read and approved the final manuscript. Received: 11 December 2008 Accepted: 12 January 2010 Published: 12 January 2010 References 1. Seabrook GR, Ray WJ, Shearman M, Hutton M: Beyond amyloid: the next generation of Alzheimer’s disease therapeutics. Mol Interv 2007, 7(5):261- 270. 2. Kidd M: Paired helical filaments in electron microscopy of Alzheimer’s Disease. Nature 1963, 197:192-193. 3. Terry R: The fine structure of neurofibrillary tangles in Alzheimer’s disease. J Neuropathol Exp Neuro 1963, 22:629-642. 4. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83(13):4913-4917. 5. Gustke N, Steiner B, Mandelkow EM, Biernat J, Meyer HE, Goedert M, Mandelkow E: The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett 1992, 307(2):199-205. 6. Ihara Y, Nukina N, Miura R, Ogawara M: Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J Biochem 1986, 99(6):1807-1810. 7. Kosik KS, Orecchio LD, Bakalis S, Neve RL: Developmentally regulated expression of specific tau sequences. Neuron 1989, 2(4):1389-1397. 8. Lace GL, Wharton SB, Ince PG: A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin Neuropathol 2007, 26(2):43-58. Page 9 of 10 9. Johnson GV, Bailey CD: Tau, where are we now?. J Alzheimers Dis 2002, 4(5):375-398. 10. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E: Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell 1995, 6(12):1887-1902. 11. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 2002, 103(1):26-35. 12. Mi K, Johnson GV: The role of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2006, 3(5):449-463. 13. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K: Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 1998, 357(2):299-309. 14. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB: Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 2007, 18(12):5060-5068. 15. Johnson GV, Hartigan JA: Tau protein in normal and Alzheimer’s disease brain: an update. J Alzheimers Dis 1999, 1(4-5):329-351. 16. Yamamoto H, Yamauchi E, Taniguchi H, Ono T, Miyamoto E: Phosphorylation of microtubule-associated protein tau by Ca2 +/calmodulin-dependent protein kinase II in its tubulin binding sites. Arch Biochem Biophys 2002, 408(2):255-262. 17. Singh TJ, Wang JZ, Novak M, Kontzekova E, Grundke-Iqbal I, Iqbal K: Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett 1996, 387(2-3):145-148. 18. Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M, Seubert P: Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/ calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J 1996, 316(Pt 2):655-660. 19. Drewes G, Trinczek B, Illenberger S, Biernat J, Schmitt-Ulms G, Meyer HE, Mandelkow EM, Mandelkow E: Microtubule-associated protein/ microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates taumicrotubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J Biol Chem 1995, 270(13):7679-7688. 20. Paudel HK: The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J Biol Chem 1997, 272(3):1777-1785. 21. Kosuga S, Tashiro E, Kajioka T, Ueki M, Shimizu Y, Imoto M: GSK-3beta directly phosphorylates and activates MARK2/PAR-1. J Biol Chem 2005, 280(52):42715-42722. 22. Song JS, Yang SD: Tau protein kinase I/GSK-3 beta/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain. J Protein Chem 1995, 14(2):95-105. 23. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002, 298(5600):1912- 1934. 24. Johnson SA, Hunter T: Kinomics: methods for deciphering the kinome. Nat Methods 2005, 2(1):17-25. 25. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293(5530):711-714. 26. Bullido MJ, Martinez-Garcia A, Tenorio R, Sastre I, Munoz DG, Frank A, Valdivieso F: Double stranded RNA activated EIF2 alpha kinase (EIF2AK2; PKR) is associated with Alzheimer’s disease. Neurobiol Aging 2007. 27. Peel AL, Bredesen DE: Activation of the cell stress kinase PKR in Alzheimer’s disease and human amyloid precursor protein transgenic mice. Neurobiol Dis 2003, 14(1):52-62. 28. Chang RC, Wong AK, Ng HK, Hugon J: Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer’s disease. Neuroreport 2002, 13(18):2429-2432. 29. Bando Y, Onuki R, Katayama T, Manabe T, Kudo T, Taira K, Tohyama M: Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson’s disease and Huntington’s disease. Neurochem Int 2005, 46(1):11-18. 30. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, et al: The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-